Viral Hepatitis C

Research and Markets - Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Hepatitis C virus affects between 130–150 million individuals every year globally of which approximately 700,000 people die. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

It was estimated that there could be rise from $18700 million to $22721.1 million in hepatitis drug market by the end of forecasting period reflecting a sluggish CAGR of 3.3%.